Artivion | CRY - Operating Expenses


Artivion reported $111.2M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Accuray USD 37.18M 567K Dec/2024
AngioDynamics USD 81.95M 1.68M Sep/2025
Artivion USD 111.2M 9.45M Dec/2025
AtriCure USD 140.72M 2.71M Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Becton, Dickinson and Co. USD 24.13B 19.54B Mar/2026
Boston Scientific USD 4.15B 107M Mar/2026
Edwards Lifesciences USD 1.13B 65.4M Mar/2026
Inogen USD 49.14M 665K Sep/2024
Integra LifeSciences USD 1.04B 673.49M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Mesa Laboratories USD 33.98M 2.03M Dec/2024
Orthofix International USD 213.79M 12.36M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
ResMed USD 925.74M 525K Mar/2026
Stryker USD 4.92B 284M Mar/2026
Surmodics USD 29.51M 274.86M Jun/2025
Tandem Diabetes Care USD 282.09M 9.97M Dec/2025
Teleflex USD 3.08B 2.55B Mar/2026
Terumo JPY 268.87B 16.12B Mar/2026
Trinity Biotech USD 14.82M 7.81M Sep/2025